Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III randomized open-label study of GB08 injection in pediatric growth hormone deficiency
CTR20252488Phase 3Active
- Sponsor
- Kexing Biopharm
- Start
- Aug 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of GB08 in growth hormone deficiency (GHD), sponsored by Kexing Biopharm. Started Aug 2025; status: active.
02
Drugs
GB08
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on CTR20252488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252488.